Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease

  • days left to enroll
  • participants needed
  • sponsor
    Thomas Zilli
Updated on 9 May 2021
positron emission tomography
alzheimer's disease
neurodegenerative disorders
senile plaques
cognitive assessment


Alzheimer's Disease (AD) is the most frequent neurodegenerative disease associated with dementia, with a constantly increasing prevalence associated with an aging population. Amyloid deposition is considered the first molecular event occurring in AD: as already showed in an animal model, a low-dose radiotherapy (RT) course is capable of reducing AD-associated amyloid- plaques and improve cognitive function. This pilot study wishes to investigate in 10 patients with a diagnosis of prodromal or early probable AD and with evidence of amyloid pathology the effectiveness of a short course low dose RT radiotherapy to reduce amyloid deposits in the human brain using molecular imaging (18F-Florbetapir) to show the effectiveness of the treatment on the specific target.

Condition Dementia, Alzheimer's Disease, alzheimer, dementia alzheimer's type
Treatment Low dose radiotherapy
Clinical Study IdentifierNCT03352258
SponsorThomas Zilli
Last Modified on9 May 2021


Yes No Not Sure

Inclusion Criteria

Ability to understand the clinical trial and give an informed consent
Clinical diagnosis of prodromal AD, or mild or moderate AD
Ability to undergo neurocognitive assessment at baseline visit, alone or accompanied by a caregiver
Amyloid PET scan positivity
Ability to follow the 5-days RT regiment, alone or accompanied by a caregiver

Exclusion Criteria

Inclusion in another disease modifying clinical trial
Previous therapeutic brain irradiation
Evidence of vascular cognitive impairment on Magnetic Resonance Imaging (MRI) (Fazekas score >1 and Wahlund score >=10/30)
Oncologic disease (excluding skin cancer) active or in remission from less than 5 years
Evidence of substance abuse (alcohol and/or other drugs) with a dependence during the previous 12 months (DSM-IV criteria)
Presence of subdural hygroma's, subdural hematomas or hydrocephalus
Significant psychiatric comorbidity as assessed during the clinical evaluation by the neurologist/geriatrician in charge
Active or recent (within 3 months) cerebral infection/haemorrhage
Immunocompromised status
Prior history of seizure
Dermatological skin disease of the scalp
Women who are pregnant or breast feeding or who intend to become pregnant during the course of the study
Lack of safe contraception, defined as: female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note